AP765A - Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. - Google Patents

Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. Download PDF

Info

Publication number
AP765A
AP765A APAP/P/1997/000976A AP9700976A AP765A AP 765 A AP765 A AP 765A AP 9700976 A AP9700976 A AP 9700976A AP 765 A AP765 A AP 765A
Authority
AP
ARIPO
Prior art keywords
ziprasidone mesylate
ziprasidone
crystals
mesylate
dihydrate
Prior art date
Application number
APAP/P/1997/000976A
Other languages
English (en)
Other versions
AP9700976A0 (en
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9700976A0 publication Critical patent/AP9700976A0/xx
Application granted granted Critical
Publication of AP765A publication Critical patent/AP765A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
APAP/P/1997/000976A 1996-05-07 1997-04-30 Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. AP765A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
AP9700976A0 AP9700976A0 (en) 1997-07-31
AP765A true AP765A (en) 1999-09-17

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000976A AP765A (en) 1996-05-07 1997-04-30 Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.

Country Status (41)

Country Link
US (1) US6245765B1 (fr)
EP (1) EP0918772B1 (fr)
JP (1) JP3494659B2 (fr)
KR (1) KR100333215B1 (fr)
CN (1) CN1091769C (fr)
AP (1) AP765A (fr)
AR (1) AR007004A1 (fr)
AT (1) ATE278689T1 (fr)
AU (1) AU731267B2 (fr)
BG (1) BG63544B1 (fr)
BR (1) BR9709889A (fr)
CA (1) CA2252898C (fr)
CO (1) CO4940466A1 (fr)
CZ (1) CZ289215B6 (fr)
DE (1) DE69731094T2 (fr)
DK (1) DK0918772T3 (fr)
DZ (1) DZ2222A1 (fr)
EA (1) EA001190B1 (fr)
EG (1) EG24076A (fr)
ES (1) ES2229342T3 (fr)
GT (1) GT199700052A (fr)
HK (1) HK1017892A1 (fr)
HR (1) HRP970236B1 (fr)
ID (1) ID16867A (fr)
IL (1) IL126591A (fr)
IS (1) IS2080B (fr)
MA (1) MA24171A1 (fr)
MY (1) MY119997A (fr)
NO (1) NO312514B1 (fr)
NZ (1) NZ332218A (fr)
OA (1) OA10909A (fr)
PL (1) PL188330B1 (fr)
PT (1) PT918772E (fr)
SI (1) SI0918772T1 (fr)
SK (1) SK282837B6 (fr)
TN (1) TNSN97074A1 (fr)
TR (1) TR199802240T2 (fr)
TW (1) TW491847B (fr)
UA (1) UA46840C2 (fr)
WO (1) WO1997042191A1 (fr)
ZA (1) ZA973876B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1286672B1 (fr) * 2000-06-02 2006-10-25 Pfizer Products Inc. S-methyl-dihydro-ziprasidone pour traiter des troubles oculaires.
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
MXPA05012317A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
KR20060015750A (ko) 2003-06-03 2006-02-20 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
CA2543805A1 (fr) 2003-10-24 2005-05-06 Gideon Pilarsky Procedes de preparation de ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (fr) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
CA2471219A1 (fr) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Preparation amelioree d'une forme anhydre du chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one (chlorhydrate de ziprasidone)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
US20060258679A1 (en) * 2005-02-11 2006-11-16 Alex Mainfeld Process of preparing ziprasidone mesylate
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (fr) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Synthese de sels d'addition acide de ziprasidone et de produits intermediaires connexes au moyen de reactions solide-gaz
WO2006098834A2 (fr) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Formes cristallines de mesylate de ziprasidone
EP1858892A1 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Mesylate de ziprasidone anhydre et son procede de preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
CA2727573A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composes diaryle et leurs utilisations
WO2012053654A1 (fr) * 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Formulation à libération prolongée pour injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (fr) * 1992-08-26 1994-03-02 Pfizer Inc. Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
WO1995000510A1 (fr) * 1993-06-28 1995-01-05 Pfizer Inc. Procedes et intermediaires pour la preparation de 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
AU730856C (en) 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (fr) * 1992-08-26 1994-03-02 Pfizer Inc. Procédé de préparation de dérivés aryl pipérazinyl-hétérocycliques
WO1995000510A1 (fr) * 1993-06-28 1995-01-05 Pfizer Inc. Procedes et intermediaires pour la preparation de 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
CZ289215B6 (cs) 2001-12-12
US6245765B1 (en) 2001-06-12
KR20000010824A (ko) 2000-02-25
IS2080B (is) 2006-02-15
SK150898A3 (en) 2000-02-14
SI0918772T1 (en) 2005-02-28
AU2174797A (en) 1997-11-26
MY119997A (en) 2005-08-30
TNSN97074A1 (fr) 2005-03-15
TR199802240T2 (fr) 1999-02-22
EP0918772B1 (fr) 2004-10-06
CO4940466A1 (es) 2000-07-24
BG102892A (en) 1999-09-30
BR9709889A (pt) 1999-08-10
DE69731094D1 (de) 2004-11-11
EA001190B1 (ru) 2000-12-25
OA10909A (en) 2001-10-26
NO985194D0 (no) 1998-11-06
SK282837B6 (sk) 2002-12-03
HRP970236A2 (en) 1998-06-30
JPH11509867A (ja) 1999-08-31
PT918772E (pt) 2004-12-31
DK0918772T3 (da) 2005-01-10
ES2229342T3 (es) 2005-04-16
WO1997042191A1 (fr) 1997-11-13
CA2252898A1 (fr) 1997-11-13
JP3494659B2 (ja) 2004-02-09
KR100333215B1 (ko) 2002-06-20
CN1091769C (zh) 2002-10-02
ATE278689T1 (de) 2004-10-15
NZ332218A (en) 2005-02-25
MA24171A1 (fr) 1997-12-31
AR007004A1 (es) 1999-10-13
HRP970236B1 (en) 2002-12-31
HK1017892A1 (en) 1999-12-03
AP9700976A0 (en) 1997-07-31
NO985194L (no) 1998-11-06
IL126591A (en) 2001-11-25
DZ2222A1 (fr) 2002-12-03
CA2252898C (fr) 2003-04-08
IL126591A0 (en) 1999-08-17
GT199700052A (es) 2001-08-29
ZA973876B (en) 1998-11-06
DE69731094T2 (de) 2006-02-23
EG24076A (en) 2008-05-11
EA199800912A1 (ru) 1999-04-29
UA46840C2 (uk) 2002-06-17
PL188330B1 (pl) 2005-01-31
PL329884A1 (en) 1999-04-12
EP0918772A1 (fr) 1999-06-02
TW491847B (en) 2002-06-21
IS4874A (is) 1998-10-20
CZ349398A3 (cs) 1999-09-15
BG63544B1 (bg) 2002-04-30
NO312514B1 (no) 2002-05-21
AU731267B2 (en) 2001-03-29
CN1216991A (zh) 1999-05-19
ID16867A (id) 1997-11-20

Similar Documents

Publication Publication Date Title
AP765A (en) Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-